Clinical trials: Retinal Vascularisation
Age Related Macular Degeneration
Foresee Home for Monitoring Age Related Macular Degeneration (AMD)
The FORESEE HOME is intended for the early detection of central and paracentral irregularities (abnormalities) in the visual field, most commonly associated with AMD.
- Trial name
- Foresee Home (NCT01010997)
- Testing
- Foresee Home
- Where
- Israel
- Volunteers
- 10 people
- Sponsor
- Notal Vision Ltd.
Macular Degeneration
Double-Masked Study of Photrex (Rostaporfin) Photodynamic Therapy in the Treatment of Age-Related Macular Degeneration
The purpose of this study is to confirm the efficacy and safety of rostaporfin (PHOTREX) photodynamic therapy (PDT) in the treatment of classic and occult subfoveal choroidal neovascularization (CNV) associated with age-related…
- Trial name
- NCT00157976
- Testing
- Photrex (rostaporfin)
- Where
- 4 sites in Bulgaria, Czechia and 2 more
- Volunteers
- 660 people
- Sponsor
- Miravant Pharmaceuticals
Macular Degeneration
Identification and Treatment of Feeder Vessels in Macular Degeneration
This study will try to identify and treat feeder vessels in age-related macular degeneration. The macula is the part of the retina in the back of the eye that determines central or best vision.
- Trial name
- NCT00018070
- Testing
- Angiography, Laser Treatment
- Where
- United States
- Volunteers
- 20 people
- Sponsor
- National Eye Institute (NEI)
Pigment Epithelial Detachment
iSONEP to Treat Persistent Pigment Epithelial Detachment (PED) in Subjects With Exudative Age-Related Macular Degeneration (AMD) or Polypoidal Choroidal Vasculopathy (PCV)
LT1009-Oph-002 is a Phase 1b study designed to evaluate the safety and potential efficacy of iSONEP following one, two or three injections of iSONEP, as needed, for the treatment of Pigment Epithelial Detachment (PED) secondary…
- Trial name
- PED (NCT01334255)
- Testing
- iSONEP (sonepcizumab/LT1009)
- Where
- 5 sites in United States
- Volunteers
- 12 people
- Sponsor
- Lpath, Inc.
Age-Related Macular Degeneration (ARMD)
Study of Ranibizumab Administered in Conjunction With Photodynamic Therapy With Verteporfin in Patients With Subfoveal Choroidal Neovascularization and Age-Related Macular Degeneration
Ranibizumab is derived from a murine monoclonal anti- vascular endothelial growth factor (VEGF) antibody and can penetrate through the many retinal cell layers following intravitreal injection.
- Trial name
- NCT00288561
- Testing
- ranibizumab
- Where
- Switzerland
- Sponsor
- Novartis
Macular Neovascularization Secondary to Age-Related Macular Degeneration
4D-150 in Patients With Macular Neovascularization Secondary to Age-Related Macular Degeneration
A Phase 3, Randomized, Double-Masked, Active-Controlled Trial in Adults with Macular Neovascularization Secondary to Age-Related Macular Degeneration
- Trial name
- NCT06864988
- Testing
- 4D-150 IVT (3E10 vg/eye), EYLEA® (aflibercept) Injection 2 mg (0.05mL)
- Where
- 94 sites in United States, Canada
- Volunteers
- 480 people
- Sponsor
- 4D Molecular Therapeutics
Choroidal Neovascularization, Macular Degeneration
Macular Photocoagulation Study (MPS)
To evaluate laser treatment of choroidal neovascularization (CNV) through randomized, controlled clinical trials. The Macular Photocoagulation Study (MPS) consisted of three sets of randomized, controlled clinical trials.
- Conditions
- Choroidal Neovascularization, Macular Degeneration, Histoplasmosis
- Trial name
- NCT00000158
- Testing
- Argon Blue-Green Laser Photocoagulation
- Sponsor
- National Eye Institute (NEI)
Conjunctivitis, Glaucoma
Feasibility Study and Preliminary Application Study on Iris OCTA
All participants will underwent imaging using the OCTA system (Zeiss) with the anterior segment optical adaptor lens. The main outcomes are iris blood flow density and vascular density.
- Conditions
- Conjunctivitis, Glaucoma, Myopia, Diabetic Retinopathy
- Trial name
- NCT03631108
- Testing
- OCTA (ZEISS)
- Volunteers
- 4,000 people, healthy volunteers welcome
- Sponsor
- Shanghai Eye Disease Prevention and Treatment Center
Choroidal Neovascularization, Age-Related Macular Degeneration
EXTEND III - Efficacy and Safety of Ranibizumab in Patients With Subfoveal Choroidal Neovascularization (CNV) Secondary to Age-related Macular Degeneration (AMD)
This study will evaluate efficacy and safety for monthly ranibizumab 0.5 mg intravitreal injections in Asian patients with subfoveal choroidal neovascularization secondary to age-related macular degeneration.
- Trial name
- NCT00470678
- Testing
- ranibizumab
- Where
- 6 sites in South Korea, Taiwan
- Volunteers
- 95 people
- Sponsor
- Novartis
Amyotrophic Lateral Sclerosis
Analysis of Capillary Retinal and Papillary Vascularization in Patients With Amyotrophic Lateral Sclerosis - CAPISLA
Amyotrophic Lateral Sclerosis, or Charcot's disease, is a neurodegenerative disease affecting motor neurons. The disease affects between 5 and 10 people per 100,000 in the world, nearly 7,000 patients are affected in France.
- Trial name
- CAPISLA (NCT04686110)
- Testing
- angiographic optical coherence tomography
- Where
- France
- Volunteers
- 94 people, healthy volunteers welcome
- Sponsor
- University Hospital, Angers
Diabetic Macular Edema, Macular Edema
Efficacy and Safety of Intravitreal Injection of Bevacizumab with and Without Oral Curcumin
The purpose of this study is to evaluate the effectiveness of adding curcumin oral treatment to bevacizumab intravitreal injection in patients with central macular edema.
- Conditions
- Diabetic Macular Edema, Macular Edema, Retinal Neovascularization
- Trial name
- NCT06595355
- Testing
- bevacizumab with oral curcumin
- Where
- Iran
- Volunteers
- 52 people
- Sponsor
- Isfahan University of Medical Sciences
Age-related Macular Degeneration (ARMD)
Switching to Aflibercept 8mg in Patients Showing Limited Response to Previous Treatment
The treatment landscape for neovascular AMD has evolved with various anti-VEGF agents since 2006. Ranibizumab initially led the way, but its limited efficacy in reducing retinal edema paved the way for aflibercept in 2011, which…
- Trial name
- NCT06683950
- Testing
- Aflibercept 8mg
- Where
- South Korea
- Volunteers
- 35 people
- Sponsor
- Kim's Eye Hospital
Age-Related Macular Degeneration
Genetic Study of Age-Related Macular Degeneration
This study will examine skin and blood cells for genetic changes related to the development of age-related macular degeneration, an eye disease that can significantly impair the ability to read, drive, and carry out daily…
- Trial name
- NCT00357578
- Where
- United States
- Volunteers
- 150 people, healthy volunteers welcome
- Sponsor
- National Eye Institute (NEI)
The Mechanism of Retinal Neovascularization of Diabetic, Retinopathy.
Clinical Research on Retinal Neovascularization of Diabetic Retinopathy
Retinal neovascularization of diabetic retinopathy might be associated with genetic risk factors and environmental risk factors.
- Trial name
- NCT01229540
- Testing
- genetic analyzer
- Where
- China
- Volunteers
- healthy volunteers welcome
- Sponsor
- Tianjin Medical University
Age-related Macular Degeneration, Subfoveal Choroidal Neovascularization
Evaluating RXI-109 to Reduce the Progression of Subretinal Fibrosis in Subjects With NVAMD
This study is designed to evaluate the safety, tolerability and clinical activity of RXI-109 administered by intravitreal injection to reduce the progression of subretinal fibrosis in subjects with advanced neovascular…
- Conditions
- Age-related Macular Degeneration, Subfoveal Choroidal Neovascularization, Subretinal Scarring, Subretinal Fibrosis
- Trial name
- NCT02599064
- Testing
- RXI-109
- Where
- United States
- Volunteers
- 9 people
- Sponsor
- RXi Pharmaceuticals, Corp.
Wet Macular Degeneration
Pilot Study of Ranibizumab With and Without Ketorolac Eyedrops for Exudative Age-related Macular Degeneration
The addition of an anti-inflammatory agent could be a valid option for controlling choroidal neovascularization, as simply inhibiting VEGF addresses neither the multifactorial pathogenesis of choroidal neovascularization nor the…
- Trial name
- NCT02060604
- Testing
- Ketorolac + Ranibizumab, Ranibizumab
- Where
- Italy
- Volunteers
- 60 people
- Sponsor
- Università degli Studi di Brescia
Proliferative Diabetic Retinopathy
Evaluation of Treatment of High riSk proLiferative Diabetic retinopathY With Intravitreal Aflibercept injectioN
To assess the safety and efficacy of intravitreal aflibercept injection in the regression of retinal neovascularization secondary to high-risk PDR.
- Trial name
- ELYSIAN (NCT02630277)
- Testing
- Aflibercept
- Volunteers
- 30 people
- Sponsor
- Valley Retina Institute
Retinal Vein Occlusion, Retinal Vein Thrombosis
Atorvastatin for the Treatment of Retinal Vein Occlusion
The ATORVO study is designed to determine whether atorvastatin (Lipitor) can improve vision, when compared to placebo
- Conditions
- Retinal Vein Occlusion, Retinal Vein Thrombosis, Central Retinal Vein Occlusion, Branch Retinal Vein Occlusion
- Trial name
- ATORVO (NCT00517257)
- Testing
- Atorvastatin
- Where
- Canada
- Volunteers
- 180 people, healthy volunteers welcome
- Sponsor
- University of Toronto
Age Related Macular Degeneration, Choroidal Neovascularization
Efficacy of Retreatments With Intravitreal Bevacizumab
Choroidal neovascularization is a leading cause of visual loss in people older than 60 years and for its treatment there had been performed multicentric studies with Lucentis (Ranibizumab) with a significant improval of visual…
- Trial name
- NCT00406744
- Testing
- Intravitreal injection of Bevacizumab
- Where
- Mexico
- Volunteers
- 20 people
- Sponsor
- Asociación para Evitar la Ceguera en México
AMD, nAMD
Pivotal 1 Study of ABBV-RGX-314 (Also Known as RGX-314) Gene Therapy Administered Via Subretinal Delivery One Time in Participants With nAMD
ABBV-RGX-314 (also known as RGX-314) is being developed as a novel one-time gene therapy for the treatment of neovascular (wet) age-related macular degeneration (wet AMD or nAMD).
- Conditions
- AMD, nAMD, Wet Age-related Macular Degeneration, wAMD
- Trial name
- ATMOSPHERE (NCT04704921)
- Testing
- ABBV-RGX-314, Ranibizumab (LUCENTIS®)
- Where
- 89 sites in United States
- Volunteers
- 671 people
- Sponsor
- AbbVie